Apellis & Sobi Team Up to Advance C3 Therapy for Rare Diseases Affecting 275,000+ Patients
Apellis Pharmaceuticals, Inc. has teamed up with Sobi to advance systemic pegcetacoplan, a targeted C3 therapy, for multiple rare diseases impacting over 275,000 patients worldwide. The strategic collaboration was announced on October 27, 2020.
The collaboration aims to jointly advance five registrational programs in hematology, nephrology, and neurology. Sobi gains global co-development and exclusive ex-US commercialization rights for systemic pegcetacoplan. The deal includes an upfront payment of $250 million and $80 million in committed development reimbursements over four years. Additionally, Sobi may pay up to $915 million in regulatory and commercial milestones plus tiered double-digit royalties.
Apellis retains U.S. commercialization rights for systemic pegcetacoplan and worldwide commercial rights for ophthalmological pegcetacoplan. The WilmerHale team representing Apellis was led by Steven Barrett, with Sarah Hogan and Mat Trachok also involved.
Through this collaboration, Apellis and Sobi aim to bring systemic pegcetacoplan to patients with rare diseases, potentially benefiting over 275,000 individuals globally. The financial terms and shared development efforts reflect the potential of this targeted C3 therapy.
